Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980527 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL2174046 | 0.89 | DPP4 (0.39) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL34473049 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL20103234 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL1561517 | 0.79 | L3MBTL1 (0.49) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL2176501 | 0.79 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL9625796 | 0.78 | L3MBTL1 (0.54) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL2665681 | 0.78 | L3MBTL1 (0.54) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL4708850 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL30212234 | 0.75 | ALDH1A1 (0.57) | ALDH1A1TSHRCHRM2OPRM1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505922-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | claimed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | claimed |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8853253-B2 | Thalidomide analogs | P2D, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8546430-B2 | Thalidomide analogs | P2D, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130035363-A1 | Thalidomide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035363-A1 | Thalidomide Analogs | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 279/4885TSHR 1619/4885CHRM2 4584/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | ALDH1A1 336/4885TSHR 1523/4885CHRM2 4372/4885 |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 279/4885TSHR 1619/4885CHRM2 4584/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | ALDH1A1 336/4885TSHR 1523/4885CHRM2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.